EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0

作者：

Douillard, Jean-Yves ^{[1
]}

Ostoros, Gyula ^{[2
]}

Cobo, Manuel ^{[3
]}

Ciuleanu, Tudor ^{[4
]}

Mccormack, Rose ^{[7
]}

Webster, Alan ^{[5
]}

Milenkova, Tsveta ^{[6
]}

机构：

[1] Ico R Gauducheau, St Herblain, France

[2] Koranyi Natl Inst Tb & Pulmonol, Budapest, Hungary

[3] Hru Carlos Haya, Malaga, Spain

[4] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania

[5] Astrazeneca, Biometr & Informat Sci, Cambridge, England

[6] Astrazeneca, Res & Dev, Cambridge, England

[7] Astrazeneca, Personalised Healthcare, Luton, Beds, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

EGFR mutation; gefitinib; NSCLC; Caucasian; circulating-free DNA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.11-020

引用

页码：S1194 / S1195

页数：2

共 50 条

[21] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
Eric Nadler
Melissa Pavilack
Janet L. Espirito
Jamyia Clark
Ancilla Fernandes
Advances in Therapy, 2020, 37 : 946 - 954
[22] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
Nadler, Eric
Pavilack, Melissa
Espirito, Janet L.
Clark, Jamyia
Fernandes, Ancilla
ADVANCES IN THERAPY, 2020, 37 (02) : 946 - 954
[23] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Schuler, A.
Huser, J.
Schaer, S.
Schmid, S.
Scherz, A.
Gautschi, O.
Mauti, L. A.
Von Briel, T.
Waibel, C.
De Nicola, L. Wannesson
Pankovics, J.
Mark, M. T.
Rothschild, S. I.
Addeo, A.
Janthur, W-D.
Siano, M.
Britschgi, C.
Frueh, M.
ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
[24] POPULATION BASED EVALUATION OF CHEMOTHERAPY USE AFTER FIRST LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Mariano, C.
Bosdet, I.
Ionescu, D.
Karsan, A.
Sun, S.
Murray, N.
Melosky, B.
Laskin, J.
Ho, C.
ANNALS OF ONCOLOGY, 2012, 23 : 412 - 412
[25] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
Gridelli, C.
De Marinis, F.
Di Maio, M.
Cortinovis, D.
Cappuzzo, F.
Mok, T.
LUNG CANCER, 2011, 71 (03) : 249 - 257
[26] Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
Green, John A.
JOURNAL OF THORACIC DISEASE, 2018, 10 : S3837 - S3839
[27] Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib
Nie, Xin
Zhang, Ping
Cheng, Gang
Wu, Xiao-Nan
Li, Lin
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 150 - 155
[28] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Lopes, de Lima G.
VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
[29] Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer
Morin-Ben Abdallah, S.
Hirsh, V.
CURRENT ONCOLOGY, 2018, 25 : S9 - S17
[30] Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Mok, Tony S. K.
Kim, Sang-We
Wu, Yi-Long
Nakagawa, Kazuhiko
Yang, Jin-Ji
Ahn, Myung-Ju
Wang, Jie
Yang, James Chih-Hsin
Lu, You
Atagi, Shinji
Ponce, Santiago
Shi, Xiaojin
Rukazenkov, Yuri
Haddad, Vincent
Thress, Kenneth S.
Soria, Jean-Charles
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4027 - +

← 1 2 3 4 5 →